Nearly two in five FDA advisory committee meetings over a decade included a patient or consumer representative whose advocacy organization took pharmaceutical industry money, according to a peer reviewed analysis published in Health Affairs Scholar and reported by STAT on October 13.
The precise figures: between 2013 and 2022, 38 percent of meetings included either a patient or a consumer representative with active ties to a pharmaceutical funded advocacy organization. For several individual committees the share was above 50 percent. In 11 percent of meetings, the representative’s organization received funding from the very sponsor whose drug was under review. The study found most of these organizational ties were not disclosed at the meetings.
The authors’ point is structural rather than personal. The FDA has established conflict of interest policies for the scientific experts on its committees, but the rules for patient and consumer representatives, who are there to supply the public perspective and who vote alongside the experts, are far less developed on industry funding of the organizations they belong to. The study does not allege payments to the representatives themselves, and a tie to a funded group does not by itself show a vote was influenced.
For drugmakers and investors the practical exposure is procedural. Advisory committee outcomes on close calls are hard to predict and move share prices, and a documented disclosure gap gives critics of any favorable vote a ready argument. Expect pressure for the agency to extend its disclosure regime to organizational funding, which would be a modest administrative change with outsized effect on how contested approvals are defended.